Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 305

1.

Association of polymorphisms in leptin and adiponectin genes with long-term outcomes in renal transplant recipients.

Gervasini G, García-Pino G, Mota-Zamorano S, Luna E, García-Cerrada M, Tormo MÁ, Cubero JJ.

Pharmacogenomics J. 2019 Dec 2. doi: 10.1038/s41397-019-0128-7. [Epub ahead of print]

PMID:
31787754
2.

Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols.

Sobas M, Rodriguez-Veiga R, Vellenga E, Paluszewska M, De la Serna J, García-Álvarez F, Gil C, Brunet S, Bergua J, González-Campos J, Ribera JM, Tormo M, González M, Fernández I, Benavente C, González-Sanmiguel JD, Esteve J, Pérez-Encinas M, Salamero O, Manso F, Lowenberg B, Sanzs MA, Montesinos P; PETHEMA, HOVON, PALG, GATLA cooperative groups.

Eur J Haematol. 2019 Nov 14. doi: 10.1111/ejh.13346. [Epub ahead of print]

PMID:
31724208
3.

Unique clinico-biological, genetic and prognostic features of adult early T cell precursor acute lymphoblastic leukemia.

Genescà E, Morgades M, Montesinos P, Barba P, Gil C, Guàrdia R, Moreno MJ, Martínez-Carballeira D, García-Cadenas I, Vives S, Ribera J, González-Campos J, González-Gil C, Zamora L, Ramírez JL, Díaz-Beya M, Mercadal S, Artola MT, Cladera A, Tormo M, Bermúdez A, Vall-Llovera F, Martínez P, Amigo ML, Monsalvo S, Novo A, Cervera M, García-Guiñon A, Juncà J, Ciudad J, Orfao A, Ribera JM.

Haematologica. 2019 Sep 19. pii: haematol.2019.225078. doi: 10.3324/haematol.2019.225078. [Epub ahead of print]

4.

Synergistic Antioncogenic Activity of Azacitidine and Curcumin in Myeloid Leukemia Cell Lines and Patient Samples.

Martín I, Navarro B, Solano C, Calabuig M, Hernández-Boluda JC, Amat P, Remigia MJ, García F, Villamón E, Tormo M.

Anticancer Res. 2019 Sep;39(9):4757-4766. doi: 10.21873/anticanres.13659.

PMID:
31519576
5.

Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis.

Alvarez-Larrán A, López-Guerra M, Rozman M, Correa JG, Hernández-Boluda JC, Tormo M, Martínez D, Martín I, Colomer D, Esteve J, Cervantes F.

Ann Hematol. 2019 Oct;98(10):2319-2328. doi: 10.1007/s00277-019-03766-z. Epub 2019 Aug 8.

PMID:
31396671
6.

Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.

Ribera J, Zamora L, Morgades M, Vives S, Granada I, Montesinos P, Gómez-Seguí I, Mercadal S, Guàrdia R, Nomdedeu J, Pratcorona M, Tormo M, Martínez-Lopez J, Hernández-Rivas JM, Ciudad J, Orfao A, González-Campos J, Barba P, Escoda L, Esteve J, Genescà E, Solé F, Feliu E, Ribera JM; Spanish PETHEMA Group; Spanish Society of Hematology.

Genes Chromosomes Cancer. 2019 Nov;58(11):815-819. doi: 10.1002/gcc.22788. Epub 2019 Aug 7.

PMID:
31340073
7.

Cytomegalovirus DNAemia in patients with de novo acute myeloid leukemia undergoing cytotoxic chemotherapy.

Tormo M, Giménez E, Calabuig M, Talaya A, Navarro B, Amat P, Martín I, Albert E, Solano C, Navarro D.

Leuk Lymphoma. 2019 Dec;60(12):3081-3083. doi: 10.1080/10428194.2019.1613541. Epub 2019 May 21. No abstract available.

PMID:
31111760
8.

Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group.

Ribera JM, García O, Moreno MJ, Barba P, García-Cadenas I, Mercadal S, Montesinos P, Barrios M, González-Campos J, Martínez-Carballeira D, Gil C, Ribera J, Vives S, Novo A, Cervera M, Serrano J, Lavilla E, Abella E, Tormo M, Amigo ML, Artola MT, Genescà E, Bravo P, García-Belmonte D, García-Guiñón A, Hernández-Rivas JM, Feliu E; PETHEMA Group of the Spanish Society of Hematology.

Cancer. 2019 Aug 15;125(16):2810-2817. doi: 10.1002/cncr.32156. Epub 2019 Apr 23.

PMID:
31012967
9.

The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients.

Ribera J, Granada I, Morgades M, Vives S, Genescà E, González C, Nomdedeu J, Escoda L, Montesinos P, Mercadal S, Coll R, González-Campos J, Abella E, Barba P, Bermúdez A, Gil C, Tormo M, Pedreño M, Martínez-Carballeira D, Hernández-Rivas JM, Orfao A, Martínez-López J, Esteve J, Bravo P, Garcia-Guiñon A, Debén G, Moraleda JM, Queizán JA, Ortín X, Moreno MJ, Feliu E, Solé F, Ribera JM; PETHEMA Group, Spanish Society of Haematology.

Br J Haematol. 2019 Jul;186(2):263-268. doi: 10.1111/bjh.15887. Epub 2019 Mar 27.

PMID:
30916384
10.

Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia.

Megías-Vericat JE, Martínez-Cuadrón D, López JM, Bergua JM, Tormo M, Serrano J, González A, de Oteyza JP, Vives S, Vidriales B, Herrera P, Vera JA, Martínez AL, de la Fuente A, Amador ML, Hernández-Rivas JÁ, Fernández MÁ, Cerveró CJ, Morillo D, Campo PH, Gorrochategui J, Primo D, Rojas JL, Guenova M, Ballesteros J, Sanz M, Montesinos P.

Mediterr J Hematol Infect Dis. 2019 Mar 1;11(1):e2019016. doi: 10.4084/MJHID.2019.016. eCollection 2019.

11.

Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia.

Piñana JL, Giménez E, Gómez MD, Pérez A, González EM, Vinuesa V, Hernández-Boluda JC, Montoro J, Salavert M, Tormo M, Amat P, Moles P, Carretero C, Balaguer-Roselló A, Sanz J, Sanz G, Solano C, Navarro D.

J Infect. 2019 May;78(5):393-401. doi: 10.1016/j.jinf.2019.02.009. Epub 2019 Feb 21.

PMID:
30797790
12.

Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy.

Labrador J, Luño E, Vellenga E, Brunet S, González-Campos J, Chillón MC, Holowiecka A, Esteve J, Bergua J, González-Sanmiguel JD, Gil C, Tormo M, Salamero O, Manso F, Fernández I, de laSerna J, Moreno MJ, Pérez-Encinas M, Krsnik I, Ribera JM, Cervera J, Calasanz MJ, Boluda B, Sobas M, Lowenberg B, Sanz MA, Montesinos P.

Leuk Lymphoma. 2019 May;60(5):1146-1155. doi: 10.1080/10428194.2018.1522438. Epub 2018 Dec 11.

PMID:
30526152
13.

A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients.

Martínez-Cuadrón D, Gil C, Serrano J, Rodríguez G, Pérez-Oteyza J, García-Boyero R, Jiménez-Bravo S, Vives S, Vidriales MB, Lavilla E, Pérez-Simón JA, Tormo M, Colorado M, Bergua J, López JA, Herrera P, Hernández-Campo P, Gorrochategui J, Primo D, Rojas JL, Villoria J, Moscardó F, Troconiz I, Linares Gómez M, Martínez-López J, Ballesteros J, Sanz M, Montesinos P; Spanish PETHEMA group.

Leuk Res. 2019 Jan;76:1-10. doi: 10.1016/j.leukres.2018.11.006. Epub 2018 Nov 13.

14.

An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens.

Sobas M, Montesinos P, Boluda B, Bernal T, Vellenga E, Nomdedeu J, González-Campos J, Chillón M, Holowiecka A, Esteve J, Bergua J, González-Sanmiguel JD, Gil-Cortes C, Tormo M, Salamero O, Manso F, Fernández I, de la Serna J, Moreno MJ, Pérez-Encinas M, Krsnik I, Ribera JM, Escoda L, Lowenberg B, Sanz MA; PETHEMA, HOVON, PALG, and GATLA cooperative groups.

Leuk Lymphoma. 2019 Apr;60(4):1030-1035. doi: 10.1080/10428194.2018.1516875. Epub 2018 Oct 15.

PMID:
30322324
15.

Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials.

Barba P, Morgades M, Montesinos P, Gil C, Fox ML, Ciudad J, Moreno MJ, González-Campos J, Genescà E, Martínez-Carballeira D, Martino R, Vives S, Guardia R, Mercadal S, Artola MT, Cladera A, Tormo M, Esteve J, Bergua J, Vall-Llovera F, Ribera J, Martínez-Sanchez P, Amigo ML, Bermúdez A, Calbacho M, Hernández-Rivas JM, Feliu E, Orfao A, Ribera JM.

Eur J Haematol. 2019 Jan;102(1):79-86. doi: 10.1111/ejh.13178. Epub 2018 Nov 22.

PMID:
30267597
16.

Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia.

Genescà E, Lazarenkov A, Morgades M, Berbis G, Ruíz-Xivillé N, Gómez-Marzo P, Ribera J, Juncà J, González-Pérez A, Mercadal S, Guardia R, Artola MT, Moreno MJ, Martínez-López J, Zamora L, Barba P, Gil C, Tormo M, Cladera A, Novo A, Pratcorona M, Nomdedeu J, González-Campos J, Almeida M, Cervera J, Montesinos P, Batlle M, Vives S, Esteve J, Feliu E, Solé F, Orfao A, Ribera JM.

J Hematol Oncol. 2018 Jul 24;11(1):96. doi: 10.1186/s13045-018-0639-8.

17.

Therapy-related acute myeloid leukemia developing 14 years after allogeneic hematopoietic stem cell transplantation, from a persistent R882H-DNMT3A mutated clone of patient origin.

Martín I, Navarro B, Villamón E, Solano C, Serrano A, Calabuig M, Amat P, Domingo F, Abellán R, García F, Olivares MD, Chaves FJ, Tormo M, Hernández-Boluda JC.

Exp Mol Pathol. 2018 Aug;105(1):139-143. doi: 10.1016/j.yexmp.2018.07.002. Epub 2018 Jul 11.

PMID:
30017658
18.

The Evolutionary Consequences of Transposon-Related Pericentromer Expansion in Melon.

Morata J, Tormo M, Alexiou KG, Vives C, Ramos-Onsins SE, Garcia-Mas J, Casacuberta JM.

Genome Biol Evol. 2018 Jun 1;10(6):1584-1595. doi: 10.1093/gbe/evy115.

19.

Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine.

Cabezón M, Bargay J, Xicoy B, García O, Borrás J, Tormo M, Marcé S, Pedro C, Valcárcel D, Jiménez MJ, Guàrdia R, Palomo L, Brunet S, Vall-Llovera F, Garcia A, Feliu E, Zamora L; CETLAM Group.

Oncotarget. 2018 Apr 10;9(27):19342-19355. doi: 10.18632/oncotarget.25046. eCollection 2018 Apr 10.

20.

Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia.

Ribera JM, García O, Gil C, Mercadal S, García-Cadenas I, Montesinos P, Barba P, Vives S, González-Campos J, Tormo M, Esteve J, López A, Moreno MJ, Ribera J, Alonso N, Bermúdez A, Amigo ML, Genescà E, García D, Vall-Llovera F, Bergua JM, Guàrdia R, Monteserín MC, Bernal T, Calbacho M, Martínez MP, Feliu E; PETHEMA Group.

Leuk Res. 2018 May;68:79-84. doi: 10.1016/j.leukres.2018.03.010. Epub 2018 Mar 19.

PMID:
29574396
21.

Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival.

Guillem V, Calabuig M, Brunet S, Esteve J, Escoda L, Gallardo D, Ribera JM, Queipo de Llano MP, Arnan M, Pedro C, Amigo ML, Martí-Tutusaus JM, García-Guiñón A, Bargay J, Sampol A, Salamero O, Font L, Talarn C, Hoyos M, Díaz-Beyá M, Garrido A, Navarro B, Nomdédeu J, Sierra J, Tormo M.

Leuk Lymphoma. 2018 Oct;59(10):2383-2393. doi: 10.1080/10428194.2017.1422858. Epub 2018 Jan 18.

PMID:
29345176
22.

Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts.

Martín I, Such E, Navarro B, Villamón E, Vicente A, Mora E, Pedrola L, Ibáñez M, López-Pavía M, Tormo M, Serrano A, Sanz MÁ, Cervera J, Sanz G.

Blood Cancer J. 2017 Nov 20;7(12):630. doi: 10.1038/s41408-017-0016-9. No abstract available.

23.

Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia.

Ribera JM, Morgades M, Montesinos P, Martino R, Barba P, Soria B, Bermúdez A, Moreno MJ, González-Campos J, Vives S, Gil C, Abella E, Guàrdia R, Martínez-Carballeira D, Martínez-Sánchez P, Amigo ML, Mercadal S, Serrano A, López-Martínez A, Vall-Llovera F, Sánchez-Sánchez MJ, Peñarrubia MJ, Calbacho M, Méndez JA, Bergua J, Cladera A, Tormo M, García-Belmonte D, Feliu E, Ciudad J, Orfao A; PETHEMA Group, Spanish Society of Hematology.

Leuk Lymphoma. 2018 Jul;59(7):1634-1643. doi: 10.1080/10428194.2017.1397661. Epub 2017 Nov 22.

PMID:
29165013
24.

Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real-world comparison.

Tormo M, Pérez-Martínez A, Calabuig M, Hernández-Boluda JC, Amat P, Navarro D, Solano C.

Mycoses. 2018 Mar;61(3):206-212. doi: 10.1111/myc.12728. Epub 2018 Jan 3.

PMID:
29125660
25.

Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group.

Nomdedeu M, Pereira A, Calvo X, Colomer J, Sole F, Arias A, Gomez C, Luño E, Cervera J, Arnan M, Pomares H, Ramos F, Oiartzabal I, Espinet B, Pedro C, Arrizabalaga B, Blanco ML, Tormo M, Hernandez-Rivas JM, Díez-Campelo M, Ortega M, Valcárcel D, Cedena MT, Collado R, Grau J, Granada I, Sanz G, Campo E, Esteve J, Costa D; Spanish MDS Group.

Leuk Res. 2017 Dec;63:85-89. doi: 10.1016/j.leukres.2017.10.011. Epub 2017 Oct 28.

PMID:
29121539
26.

Copy number profiling of adult relapsed B-cell precursor acute lymphoblastic leukemia reveals potential leukemia progression mechanisms.

Ribera J, Zamora L, Morgades M, Mallo M, Solanes N, Batlle M, Vives S, Granada I, Juncà J, Malinverni R, Genescà E, Guàrdia R, Mercadal S, Escoda L, Martinez-Lopez J, Tormo M, Esteve J, Pratcorona M, Martinez-Losada C, Solé F, Feliu E, Ribera JM; Spanish PETHEMA Group and the Spanish Society of Hematology.

Genes Chromosomes Cancer. 2017 Nov;56(11):810-820. doi: 10.1002/gcc.22486. Epub 2017 Aug 26.

PMID:
28758283
27.

Post-Traumatic Stress Disorder and other mental disorders in the general population after Lorca's earthquakes, 2011 (Murcia, Spain): A cross-sectional study.

Navarro-Mateu F, Salmerón D, Vilagut G, Tormo MJ, Ruíz-Merino G, Escámez T, Júdez J, Martínez S, Koenen KC, Navarro C, Alonso J, Kessler RC.

PLoS One. 2017 Jul 19;12(7):e0179690. doi: 10.1371/journal.pone.0179690. eCollection 2017.

28.

Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group.

Ramos F, Robledo C, Pereira A, Pedro C, Benito R, de Paz R, Del Rey M, Insunza A, Tormo M, Díez-Campelo M, Xicoy B, Salido E, Sánchez-Del-Real J, Arenillas L, Florensa L, Luño E, Del Cañizo C, Sanz GF, María Hernández-Rivas J; Spanish Group for Myelodysplastic Syndromes (GESMD).

Am J Hematol. 2017 Sep;92(9):E534-E541. doi: 10.1002/ajh.24813. Epub 2017 Jul 19.

29.

Oxidative imbalance in low/intermediate-1-risk myelodysplastic syndrome patients: The influence of iron overload.

Ivars D, Orero MT, Javier K, Díaz-Vico L, García-Giménez JL, Mena S, Tormos C, Egea M, Pérez PL, Arrizabalaga B, Ruiz MÁ, Yagüe N, Tormo M, Sancho-Tello R, Gomes A, Algueró C, O'Connor JE, Sáez GT, Carbonell F, Collado R.

Clin Biochem. 2017 Nov;50(16-17):911-917. doi: 10.1016/j.clinbiochem.2017.05.018. Epub 2017 May 29.

PMID:
28571970
30.

Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia.

Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, Mercadal S, González-Campos J, Moreno MJ, Barba P, Cervera M, Barrios M, Novo A, Bernal T, Hernández-Rivas JM, Abella E, Amigo ML, Tormo M, Martino R, Lavilla E, Bergua J, Serrano A, García-Belmonte D, Guàrdia R, Grau J, Feliu E; PETHEMA Group, Spanish Society of Hematology.

Leuk Lymphoma. 2018 Jan;59(1):146-154. doi: 10.1080/10428194.2017.1326596. Epub 2017 May 30.

PMID:
28554259
31.

Aromatic DNA adducts and breast cancer risk: a case-cohort study within the EPIC-Spain.

Agudo A, Peluso M, Munnia A, Luján-Barroso L, Barricarte A, Amiano P, Navarro C, Sánchez MJ, Quirós JR, Ardanaz E, Larrañaga N, Tormo MJ, Chirlaque MD, Rodríguez-Barranco M, Sánchez-Cantalejo E, Cellai F, Bonet C, Sala N, González CA.

Carcinogenesis. 2017 Jul 1;38(7):691-698. doi: 10.1093/carcin/bgx047.

PMID:
28535209
32.

Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin.

Rodríguez-Veiga R, Igual B, Montesinos P, Tormo M, Sayas MJ, Linares M, Fernández JM, Salvador A, Maceira-González A, Estornell J, Calabuig M, Pedreño M, Roig M, Sanz J, Sanz G, Carretero C, Boluda B, Martínez-Cuadrón D, Sanz MÁ; spanish PETHEMA group.

Ann Hematol. 2017 Jul;96(7):1077-1084. doi: 10.1007/s00277-017-3004-z. Epub 2017 Apr 28.

PMID:
28451804
33.

Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).

Calvo X, Arenillas L, Luño E, Senent L, Arnan M, Ramos F, Pedro C, Tormo M, Montoro J, Díez-Campelo M, Blanco ML, Arrizabalaga B, Xicoy B, Bonanad S, Jerez A, Nomdedeu M, Ferrer A, Sanz GF, Florensa L.

Am J Hematol. 2017 Jul;92(7):614-621. doi: 10.1002/ajh.24732. Epub 2017 May 9.

34.

Excess mortality in the myelodysplastic syndromes.

Nomdedeu M, Pereira A, Ramos F, Valcárcel D, Costa D, Arnan M, Calvo X, Pomares H, Luño E, Díaz-Campelo M, Collado R, de Paz R, Falantes JF, Pedro C, Marco J, Oirtzabal I, Sánchez-García J, Tormo M, Cedena MT, Nomdedeu B, Sanz G; Spanish MDS Group.

Am J Hematol. 2017 Feb;92(2):149-154. doi: 10.1002/ajh.24606. Epub 2016 Dec 7.

35.

Negative impact on clinical outcome of the mutational co-occurrence of SF3B1 and DNMT3A in refractory anemia with ring sideroblasts (RARS).

Martín I, Such E, Navarro B, Vicente A, López-Pavía M, Ibáñez M, Tormo M, Villamón E, Gómez-Seguí I, Luna I, Oltra S, Pedrola L, Sanz MA, Cervera J, Sanz G.

Leuk Lymphoma. 2017 Jul;58(7):1686-1693. doi: 10.1080/10428194.2016.1246725. Epub 2016 Oct 24.

PMID:
27771989
36.

Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes.

Calvo X, Arenillas L, Luño E, Senent L, Arnan M, Ramos F, Ardanaz MT, Pedro C, Tormo M, Montoro J, Díez-Campelo M, Arrizabalaga B, Xicoy B, Bonanad S, Jerez A, Nomdedeu B, Ferrer A, Sanz GF, Florensa L.

Mod Pathol. 2016 Dec;29(12):1541-1551. doi: 10.1038/modpathol.2016.146. Epub 2016 Aug 26.

37.

Association of Plasma Phospholipid n-3 and n-6 Polyunsaturated Fatty Acids with Type 2 Diabetes: The EPIC-InterAct Case-Cohort Study.

Forouhi NG, Imamura F, Sharp SJ, Koulman A, Schulze MB, Zheng J, Ye Z, Sluijs I, Guevara M, Huerta JM, Kröger J, Wang LY, Summerhill K, Griffin JL, Feskens EJ, Affret A, Amiano P, Boeing H, Dow C, Fagherazzi G, Franks PW, Gonzalez C, Kaaks R, Key TJ, Khaw KT, Kühn T, Mortensen LM, Nilsson PM, Overvad K, Pala V, Palli D, Panico S, Quirós JR, Rodriguez-Barranco M, Rolandsson O, Sacerdote C, Scalbert A, Slimani N, Spijkerman AM, Tjonneland A, Tormo MJ, Tumino R, van der A DL, van der Schouw YT, Langenberg C, Riboli E, Wareham NJ.

PLoS Med. 2016 Jul 19;13(7):e1002094. doi: 10.1371/journal.pmed.1002094. eCollection 2016 Jul.

38.

Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes.

Arenillas L, Calvo X, Luño E, Senent L, Alonso E, Ramos F, Ardanaz MT, Pedro C, Tormo M, Marco V, Montoro J, Díez-Campelo M, Brunet S, Arrizabalaga B, Xicoy B, Andreu R, Bonanad S, Jerez A, Nomdedeu B, Ferrer A, Sanz GF, Florensa L.

J Clin Oncol. 2016 Sep 20;34(27):3284-92. doi: 10.1200/JCO.2016.66.9705. Epub 2016 Jul 5.

PMID:
27382099
39.

Feasibility of the AML profiler (Skyline™ Array) for patient risk stratification in a multicentre trial: a preliminary comparison with the conventional approach.

Nomdedéu JF, Puigdecanet E, Bussaglia E, Hernández JJ, Carricondo M, Estivill C, Martí-Tutusaus JM, Tormo M, Zamora L, Serrano E, Perea G, de Llano MPQ, García A, Sánchez-Ortega I, Ribera JM, Nonell L, Aventin A, Solé F, Brunet MS, Sierra J.

Hematol Oncol. 2017 Dec;35(4):778-788. doi: 10.1002/hon.2304. Epub 2016 May 3.

PMID:
27140599
40.

Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis.

Ramos F, Robledo C, Izquierdo-García FM, Suárez-Vilela D, Benito R, Fuertes M, Insunza A, Barragán E, Del Rey M, García-Ruiz de Morales JM, Tormo M, Salido E, Zamora L, Pedro C, Sánchez-Del-Real J, Díez-Campelo M, Del Cañizo C, Sanz GF, Hernández-Rivas JM; Spanish Group for Myelodysplastic Syndromes (GESMD).

Oncotarget. 2016 May 24;7(21):30492-503. doi: 10.18632/oncotarget.9026.

41.

Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols.

Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, Brunet S, Bergua J, Tormo M, García-Boyero R, Sarrà J, Del Potro E, Grande C, Barba P, Bernal T, Amigo ML, Grau J, Cervera J, Feliu E; PETHEMA Group, Spanish Society of Hematology.

Leuk Lymphoma. 2017 Jan;58(1):145-152. Epub 2016 Apr 27.

PMID:
27122129
42.

Work, household, and leisure-time physical activity and risk of mortality in the EPIC-Spain cohort.

Huerta JM, Chirlaque MD, Tormo MJ, Buckland G, Ardanaz E, Arriola L, Gavrila D, Salmerón D, Cirera L, Carpe B, Molina-Montes E, Chamosa S, Travier N, Quirós JR, Barricarte A, Agudo A, Sánchez MJ, Navarro C.

Prev Med. 2016 Apr;85:106-12. doi: 10.1016/j.ypmed.2016.02.009. Epub 2016 Feb 6.

PMID:
26861751
43.

Impact of anaemia on health-related quality of life and cardiac remodelling in patients with lower risk myelodysplastic syndromes. Results of GlobQoL study.

Ramos F, Pedro C, Tormo M, de Paz R, Font P, Luño E, Caballero M, Solano F, Almagro M, Xicoy B, Jiménez M.

Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12426. Epub 2016 Jan 4.

PMID:
26729645
44.

Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study.

Valcárcel D, Sanz G, Ortega M, Nomdedeu B, Luño E, Diez-Campelo M, Ardanaz MT, Pedro C, Montoro J, Collado R, Andreu R, Marco V, Cedena MT, de Paz R, Tormo M, Xicoy B, Ramos F, Bargay J, Gonzalez B, Brunet S, Muñoz JA, Gomez V, Bailén A, Sanchez J, Merchán B, del Cañizo C, Vallespí T; Grupo Español de Síndromes Mielodisplásicos (GESMD).

Lancet Haematol. 2015 Jun;2(6):e260-6. doi: 10.1016/S2352-3026(15)00067-8. Epub 2015 May 20.

PMID:
26688236
45.

Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group.

Ribera JM, García O, Oriol A, Gil C, Montesinos P, Bernal T, González-Campos J, Lavilla E, Ribera J, Brunet S, Martínez MP, Tormo M, Genescà E, Barba P, Sarrà J, Monteserín MC, Soria B, Colorado M, Cladera A, García-Guiñón A, Calbacho M, Serrano A, Ortín X, Pedreño M, Amigo ML, Escoda L, Feliu E; PETHEMA Group, Spanish Society of Hematology.

Leuk Res. 2016 Feb;41:12-20. doi: 10.1016/j.leukres.2015.11.012. Epub 2015 Dec 2.

PMID:
26686475
46.

The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab.

Forero-Castro M, Robledo C, Lumbreras E, Benito R, Hernández-Sánchez JM, Hernández-Sánchez M, García JL, Corchete-Sánchez LA, Tormo M, Barba P, Menárguez J, Ribera J, Grande C, Escoda L, Olivier C, Carrillo E, García de Coca A, Ribera JM, Hernández-Rivas JM.

Br J Haematol. 2016 Feb;172(3):428-38. doi: 10.1111/bjh.13849. Epub 2015 Nov 16.

PMID:
26567765
47.

The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.

Díaz-Beyá M, Brunet S, Nomdedéu J, Pratcorona M, Cordeiro A, Gallardo D, Escoda L, Tormo M, Heras I, Ribera JM, Duarte R, de Llano MP, Bargay J, Sampol A, Nomdedeu M, Risueño RM, Hoyos M, Sierra J, Monzo M, Navarro A, Esteve J; Cooperative AML group CETLAM.

Oncotarget. 2015 Oct 13;6(31):31613-27. doi: 10.18632/oncotarget.5148.

48.

The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.

Díaz-Beyá M, Brunet S, Nomdedéu J, Cordeiro A, Tormo M, Escoda L, Ribera JM, Arnan M, Heras I, Gallardo D, Bargay J, Queipo de Llano MP, Salamero O, Martí JM, Sampol A, Pedro C, Hoyos M, Pratcorona M, Castellano JJ, Nomdedeu M, Risueño RM, Sierra J, Monzó M, Navarro A, Esteve J.

Blood Cancer J. 2015 Oct 2;5:e352. doi: 10.1038/bcj.2015.76.

49.

Prevalence of Mental Disorders in the South-East of Spain, One of the European Regions Most Affected by the Economic Crisis: The Cross-Sectional PEGASUS-Murcia Project.

Navarro-Mateu F, Tormo MJ, Salmerón D, Vilagut G, Navarro C, Ruíz-Merino G, Escámez T, Júdez J, Martínez S, Kessler RC, Alonso J.

PLoS One. 2015 Sep 22;10(9):e0137293. doi: 10.1371/journal.pone.0137293. eCollection 2015.

50.

Complex measurements may be required to establish the prognostic impact of immunophenotypic markers in AML.

García-Dabrio MC, Hoyos M, Brunet S, Tormo M, Ribera JM, Esteve J, Gallardo D, Duarte RF, de Llano MP, Bargay J, Martí-Tutusaus JM, Heras I, Garcia A, Salamero O, Aventin A, Lecrevisse Q, Orfao A, Sierra J, Nomdedéu JF.

Am J Clin Pathol. 2015 Sep;144(3):484-92. doi: 10.1309/AJCPRL6XSVFMLH9V.

PMID:
26276779

Supplemental Content

Support Center